Literature DB >> 12429910

Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/SDI1).

Hongming Zhu1, Bey-Dih Chang, Takeshi Uchiumi, Igor B Roninson.   

Abstract

Induction of p21 (WAF1/CIP1/SDI1), a physiological mediator of cell cycle arrest, inhibits multiple genes involved in cell division. We have investigated the determinants of p21- mediated inhibition of two of these genes, polo-like kinase 1 (PLK1) and topoisomerase IIalpha (TOPO IIalpha) p21 expression from an inducible promoter in human HT1080 cells rapidly decreases cellular levels of PLK1 and TOPO IIalpha promoters in transient and stable transfection assays. Promoter mutagenesis studies show that inhibition of the PLK1 promoter by p21 is mediated in part by tandem sequences CDE (cell cycle-dependent element) and CHR (cell cycle genes homology region). p21 response of the TOPO IIalpha promoter inhibition and the effects of promoter mutations differ under the conditions of growth arrest produced by p21 induction or by mimosine, a cell cycle inhibitor that increases p21 RNA but not protein expression in HT1080 cells. These results indicate that inhibition of cell division-associated genes by p21 is mediated by different but overlapping mechanisms, which are not a general con-sequence of cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429910

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  24 in total

Review 1.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

2.  Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.

Authors:  Jacquelyn J Bower; Yingchun Zhou; Tong Zhou; Dennis A Simpson; Sonnet J Arlander; Richard S Paules; Marila Cordeiro-Stone; William K Kaufmann
Journal:  Cell Cycle       Date:  2010-04-15       Impact factor: 4.534

3.  p53-dependent repression of polo-like kinase-1 (PLK1).

Authors:  Lynsey McKenzie; Sharon King; Lynnette Marcar; Sam Nicol; Sylvia S Dias; Katie Schumm; Pamela Robertson; Jean-Christophe Bourdon; Neil Perkins; Frances Fuller-Pace; David W Meek
Journal:  Cell Cycle       Date:  2010-10-04       Impact factor: 4.534

4.  Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics.

Authors:  Paraskevi Giannakakou; Michel Nakano; Kyriacos C Nicolaou; Aurora O'Brate; Jian Yu; Mikhail V Blagosklonny; Urs F Greber; Tito Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-26       Impact factor: 11.205

5.  Topoisomerase II alpha is required for embryonic development and liver regeneration in zebrafish.

Authors:  Michael Dovey; E Elizabeth Patton; Teresa Bowman; Trista North; Wolfram Goessling; Yi Zhou; Leonard I Zon
Journal:  Mol Cell Biol       Date:  2009-04-20       Impact factor: 4.272

Review 6.  The role of polo-like kinase 1 in carcinogenesis: cause or consequence?

Authors:  Brian D Cholewa; Xiaoqi Liu; Nihal Ahmad
Journal:  Cancer Res       Date:  2013-11-21       Impact factor: 12.701

7.  Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.

Authors:  Sharon I King; Colin A Purdie; Susan E Bray; Philip R Quinlan; Lee B Jordan; Alastair M Thompson; David W Meek
Journal:  Breast Cancer Res       Date:  2012-03-08       Impact factor: 6.466

Review 8.  One function--multiple mechanisms: the manifold activities of p53 as a transcriptional repressor.

Authors:  Levin Böhlig; Karen Rother
Journal:  J Biomed Biotechnol       Date:  2011-03-08

9.  The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.

Authors:  R Sumanth Iyer; Samantha M Nicol; Philip R Quinlan; Alastair M Thompson; David W Meek; Frances V Fuller-Pace
Journal:  Cell Cycle       Date:  2014-03-06       Impact factor: 4.534

Review 10.  Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers.

Authors:  Gennadi V Glinsky
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 6.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.